P2RY12 and coronary artery disorder: The addition of ticagrelor to aspirin reduced cardiovascular death and coronary heart disease by 22% and 34%, respectively, in patients with diabetes, emphasizing the importance of potent P2Y12 inhibitors in patients with elevated cardiovascular risk.